MX2023005695A - Administracion de agonista de sting, inhibidores de puntos de control y radiacion. - Google Patents
Administracion de agonista de sting, inhibidores de puntos de control y radiacion.Info
- Publication number
- MX2023005695A MX2023005695A MX2023005695A MX2023005695A MX2023005695A MX 2023005695 A MX2023005695 A MX 2023005695A MX 2023005695 A MX2023005695 A MX 2023005695A MX 2023005695 A MX2023005695 A MX 2023005695A MX 2023005695 A MX2023005695 A MX 2023005695A
- Authority
- MX
- Mexico
- Prior art keywords
- radiation
- checkpoint inhibitors
- administration
- sting agonist
- need
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- 230000005855 radiation Effects 0.000 title abstract 2
- 229940044665 STING agonist Drugs 0.000 title 1
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
La presente descripción proporciona métodos, composiciones farmacéuticas y kits para tratar el cáncer en pacientes que lo necesiten. Los métodos comprenden administrar a un paciente que lo necesite un agonista de STING (estimulador de genes de interferón), tal como el Compuesto n.º 14 tal como se define en la descripción, o una sal farmacéuticamente aceptable de este, en combinación con uno o más inhibidores de puntos de control y radiación. También se proporcionan medicamentos para el uso en el tratamiento del cáncer.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115398P | 2020-11-18 | 2020-11-18 | |
| US202163140125P | 2021-01-21 | 2021-01-21 | |
| US202163184295P | 2021-05-05 | 2021-05-05 | |
| US202163275480P | 2021-11-04 | 2021-11-04 | |
| PCT/IB2021/060679 WO2022107027A1 (en) | 2020-11-18 | 2021-11-18 | Administration of sting agonist, checkpoint inhibitors, and radiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005695A true MX2023005695A (es) | 2023-05-29 |
Family
ID=79287967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005695A MX2023005695A (es) | 2020-11-18 | 2021-11-18 | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4247385A1 (es) |
| JP (1) | JP2023550740A (es) |
| KR (1) | KR20230110254A (es) |
| AU (1) | AU2021383424A1 (es) |
| CA (1) | CA3196529A1 (es) |
| MX (1) | MX2023005695A (es) |
| TW (1) | TW202233206A (es) |
| WO (1) | WO2022107027A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| EP3558358A4 (en) * | 2016-12-20 | 2020-09-30 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUKLEOTIDE STING AGONISTS FOR CANCER TREATMENT |
| JP2020529421A (ja) * | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| WO2020049534A1 (en) * | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
| US20220409734A1 (en) * | 2019-05-10 | 2022-12-29 | Yutaka Nishimoto | Antibody drug conjugates |
| JP2022540605A (ja) * | 2019-07-09 | 2022-09-16 | 武田薬品工業株式会社 | Ｓｔｉｎｇアゴニスト及びチェックポイント阻害剤の投与 |
-
2021
- 2021-11-18 JP JP2023529980A patent/JP2023550740A/ja active Pending
- 2021-11-18 KR KR1020237015686A patent/KR20230110254A/ko unknown
- 2021-11-18 WO PCT/IB2021/060679 patent/WO2022107027A1/en active Application Filing
- 2021-11-18 CA CA3196529A patent/CA3196529A1/en active Pending
- 2021-11-18 AU AU2021383424A patent/AU2021383424A1/en active Pending
- 2021-11-18 TW TW110142964A patent/TW202233206A/zh unknown
- 2021-11-18 EP EP21840113.1A patent/EP4247385A1/en active Pending
- 2021-11-18 MX MX2023005695A patent/MX2023005695A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023550740A (ja) | 2023-12-05 |
| EP4247385A1 (en) | 2023-09-27 |
| CA3196529A1 (en) | 2022-05-27 |
| KR20230110254A (ko) | 2023-07-21 |
| AU2021383424A1 (en) | 2023-06-08 |
| WO2022107027A1 (en) | 2022-05-27 |
| AU2021383424A9 (en) | 2024-02-08 |
| TW202233206A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
| HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
| EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| BR112022009283A2 (pt) | Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| ZA202203202B (en) | Monocyclic agonists of stimulator of interferon genes sting | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| KR960700734A (ko) | 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers) | |
| MX2023010394A (es) | Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd. | |
| AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| ZA202203203B (en) | Bicyclic agonists of stimulator of interferon genes sting |